Novartis launches Cosentyx (2016)
Novartis won US approval for secukinumab (Cosentyx) in psoriatic arthritis, the first IL-17A inhibitor cleared for the disease, based on the FUTURE trials.
Cosentyx expanded across psoriasis and spondyloarthritis indications.
It grew into a multibillion-dollar franchise, proving the commercial ceiling for IL-17 drugs in these diseases.
It marks the market sonelokimab is entering and the incumbent revenue a newer, dual-signal drug would try to take share from.
